Click Here!Click Here!
Home / Health / Novartis says Alcon’s Travatan receives EU approval
Novartis says Alcon’s Travatan receives EU approval

Novartis says Alcon’s Travatan receives EU approval


ZURICH (Reuters) – Swiss curative organisation Novartis pronounced on Tuesday a European Commission had authorized an additional diagnosis for a eyecare section Alcon’s Travatan diagnosis for glaucoma, a chronic, sight-threatening eye disease.

Alcon pronounced in a matter on Tuesday a Travatan eye drops resolution had been authorized to revoke towering intraocular vigour in pediatric patients.

“We are gratified to accept a new EU pediatric denote of Travatan, that serve strengthens Alcon’s globally heading glaucoma portfolio,” Jeff George, tellurian conduct of Alcon, pronounced in a statement.

(Reporting by Joshua Franklin; Editing by Prateek Chatterjee)

About admin

Scroll To Top